Issues: Vax Specific

Anthrax

Hepatitis B

Hib 

HPV

Influenza

Lyme Disease
Meningococcal

MMR    

Pneumococcal    

Polio

Rotavirus

● Smallpox

Tdap/Td

Varicella

Yellow Fever

 

Issues: Misc

Exemptions

Legislation 

New Vax Status

Thimerosal

Independent Vax  Safety Board

 

Vaccine Info

2014 Schedule

ACIP Recs

Components
IOM Reports

● Vax Injury Comp Program
Manufacturer Links

Package Inserts

Reporting AEs

Thimerosal Table

VAERS

VISs

 

Links
 

Search
 

About IVS

Faculty Biographies

Publications

Donations

 

Email IVS

 

Disclaimers & Privacy
 

 

Institute for Vaccine Safety

Johns Hopkins Bloomberg School of Public Health

615 N. Wolfe Street

Room W5041

Baltimore, MD 21205

www.vaccinesafety.edu

 

 

Components of
Seasonal Influenza Vaccines 2013/14
Excipients Table
Allergens Table
Components Table
Components: Afluria-Flublok
Components: Flucelvax-Fluvirin
     

Proprietary Name

Fluzone Fluzone Quad Fluzone High-Dose Fluzone Intradermal

Manufacturers

sanofi pasteur sanofi pasteur sanofi pasteur sanofi pasteur

Viability

Inactivated

Inactivated

 

 

Approved Ages

6 mos and older

 

6 mos and older

 

65 yrs and older

18-64 yrs

Pediatric Dose

6-35 mos: 0.25 mL

3 yrs: 0.5 mL

6-35 mos: 0.25 mL

3 yrs: 0.5 mL

NA

NA

Adult Dose

0.5 mL

0.5 mL

0.5 mL

0.1 mL

Route

Intramuscular

Intramuscular

Intramuscular

Intradermal

Dose form

Solution

Solution

Solution

Solution

Appearance

Clear and slightly opalescent

Clear and slightly opalescent

Clear and slightly opalescent

Clear and slightly opalescent

Concentration (per 0.5 mL)

A/California/07/2009 X-179A (H1N1), 15 mcg

A/Texas/50/2012 X-223A  (H3N2), 15 mcg

B/Massachusetts/02/2012, 15 mcg

A/California/07/2009 X-179A (H1N1), 15 mcg

A/Texas/50/2012 X-8 223A (H3N2), an A/Victoria/361 /2011-like virus, 15 mcg

B/Massachusetts/02/2012, B Yamagata lineage, 15 mcg

B/Brisbane/60/2008, B Victoria lineage, 15 mcg

A/California/07/2009 NYMC X-179A (H1N1), 60 mcg

A/Texas/50/2012 X-223A (H3N2), 60 mcg

B/Massachusetts/02/2012, 60 mcg 

A/California/07/2009 NYMC X-179A (H1N1), 9 mcg

A/Texas/50/2012 X-223A (H3N2), 9 mcg

B/Massachusetts/02/2012, 9 mcg

Excipients (per 0.5 mL dose)

Gelatin, 0.05%

Formaldehyde, ≤100 mcg

Octylphenol Ethoxylate, ≤150 mcg

Sodium phosphate-buffered isotonic sodium chloride solution, "quantity sufficient to appropriate volume"

Thimerosal, 25 mcg mercury (none in Pediatric Dose)

Gelatin, 0.05%

Formaldehyde, ≤100 mcg

Octylphenol Ethoxylate, ≤250 mcg

Sodium phosphate-buffered isotonic sodium chloride solution, "quantity sufficient to appropriate volume"

Formaldehyde, ≤100 mcg

Octylphenol Ethoxylate, ≤250 mcg

Sodium phosphate-buffered isotonic sodium chloride solution, "quantity sufficient to appropriate volume"

Formaldehyde,  ≤20 mcg

Octylphenol Ethoxylate, ≤50 mcg

Sodium phosphate-buffered isotonic sodium chloride solution, "quantity sufficient to appropriate volume"

Adjuvant

None

None

None

None

Allergens

Egg proteins, residual

Gelatin, 0.05%

Thimerosal, 25 mcg mercury only in multi-dose vial

Egg proteins, residual

Gelatin, 0.05%

 

Egg proteins, residual

Egg proteins, residual

 

Preservatives

Single-dose: No preservatives

Multi-dose: Thimerosal, 25 mcg of mercury

None

None

None

Media

Allantoic fluid of embryonated hen eggs

Allantoic fluid of embryonated hen eggs

Allantoic fluid of embryonated hen eggs

Allantoic fluid of embryonated hen eggs

Packaging

Prefilled syringe (0.25 and 0.5 mL)

Single-dose vial, 0.5 mL

Multi-dose vial, 5 mL

Prefilled syringe (0.25 and 0.5 mL),

Single-dose vial, 0.5 mL 

Prefilled syringe, 0.5 mL

Prefilled microinjection system, 0.1 mL

Routine Storage

2 to 8 C (36-46 F)

Do not freeze

2 to 8 C (36-46 F)

Do not freeze

2 to 8 C (36-46 F)

Do not freeze

2 to 8 C (36-46 F)

Do not freeze

Package Insert date

Apr 2013

Jun 2013

Apr 2013

Apr 2013

 

This page was last updated on February 12, 2014

2014 Institute for Vaccine Safety